Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease

Results: A total of 21 children (median age¼ 9 years) at high risk for IFD were included in the analysis. No significant clinical adverse event occurred, and end of treatment values of parameters of renal and hepatic function in serum were not different from baseline. Proven or probable breakthrough IFD did not occur in any of the patients. In 9 out of 11 patients in whom plasma micafungin concentrations were assessed, the first trough concentration exceeded 150 ng/mL, a concentration proposed to be effective for prophylaxis. Conclusions: Our data indicate that micafungin administered twice weekly at a dosage of 3 – 4 mg/kg of bodyweight could be a convenient, safe and efficient alternative for antifungal prophylaxis in children at high risk for IFD.